Labcorp's Trading Volume Surges 34% to $191 Million, Securing 487th Spot in Daily Rankings

On April 24, 2025, Labcorp's trading volume reached $191 million, marking a 34.01% increase from the previous day. This surge placed Labcorp at the 487th position in terms of trading volume for the day. Additionally, Labcorp's stock price has been on an upward trajectory, rising by 1.98% over the past three days, with a cumulative increase of 7.71%.

Labcorp has recently expanded its precision oncology portfolio with two innovative solutions. The first is Labcorp Plasma Detect, a blood-based test designed to assess the risk of disease recurrence in stage III colon cancer patients. This test utilizes whole-genome sequencing to detect circulating tumor DNA, providing a more accurate assessment of molecular residual disease. The second solution is PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the FDA. This assay helps oncologists identify patients who may benefit from targeted treatments, all from a simple blood draw.

Labcorp Plasma Detect is particularly significant for stage III colon cancer patients, who have a nearly 30% recurrence rate within five years. The test detects cancer recurrence risk that conventional methods might miss, helping to identify patients who could benefit from additional treatment or therapy. The test combines a whole-genome sequencing approach with proprietary bioinformatics to deliver ctDNA detection down to a limit of detection of 0.005%. Results are available approximately 14 days after Labcorp receives the initial sample, and seven days for subsequent monitoring time points for each patient.

PGDx elio plasma focus Dx is the first and only kitted pan-solid tumor liquid biopsy test to receive De Novo authorization from the FDA. This assay provides oncologists with a validated tool to assess various solid tumors for targeted treatment selection. The kitted model allows clinical laboratories and hospitals to retain control over patient specimens and data for research, care management, and other clinical purposes. Once implemented, this rapid, scalable liquid biopsy genomic test provides actionable findings within a 4-to-5-day turnaround time, from isolated nucleic acid to variant report.